Washington: US regulators are not targeting India, despite a series of import restrictions on drugs from the major US trading partner, the head of the US Food and Drug Administration said today.
FDA Commissioner Margaret Hamburg briefed reporters after her first official trip to India, where she met with government and industry leaders earlier this month.
India is the second largest US supplier of prescription and over-the-counter drugs, and its big pharma companies Ranbaxy and Wockhardt have faced a series of US import restrictions over safety concerns.
"We are not targeting Indian companies. We are undertaking our required regulatory activities," Hamburg said.
"When products are sold in the United States for use by American citizens, then those products have to meet our standards."
Hamburg described as "encouraging" her conversations with high level representatives during her eight-day trip to India, the United States' third largest trading partner.
The FDA has 12 staff members in India, and plans to expand to 19, she added, describing the nation as "particularly important" to US food and drug trade.
"The fact that we have increased our presence in India is true but it reflects that fact that India is a very significant and growing player in the US marketplace with respect to both pharmaceutical products and food."